Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

TLR4 blockade in rheumatoid arthritis disappoints in phase II trial

11 Feb 2020

Blocking the toll-like receptor (TLR) 4 pathway with NI-0101, a first-in-class humanized monoclonal antibody, has failed to improve disease parameters in rheumatoid arthritis (RA) in a phase II trial.

The trial randomized 90 ACPA-positive RA patients with inadequate response to methotrexate to receive either NI-0101 (5 mg/kg every 2 weeks; n=61) or placebo (n=29) for 12 weeks. Of these, 86 completed the study.

Researchers evaluated treatment effect on the following measures: Disease Activity Score (28-joint count) with C reactive protein (DAS28-CRP), European League Against Rheumatism (EULAR) good and moderate responses, and American College of Rheumatology (ACR) 20, ACR50 and ACR70 responses. They conducted subgroup analyses defined by biomarkers and reported safety.

Efficacy endpoints did not significantly differ between the active and placebo treatment groups. In subgroup analyses that used baseline parameters as covariants, no patient population particularly benefitted from NI-0101.

The incidence of treatment-emergent adverse events was similar in the two treatment groups, recorded in 51.7 percent of patients on placebo and in 52.5 percent of those on NI-0101.

The present data show that blocking the TLR4 pathway alone does not produce improvements in RA, according to the researchers. Broader and/or earlier inhibitory approaches may be needed for successful targeting of innate immune pathways in RA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.